Peter Attia MD"Anti-Aging" Drugs — NAD, metformin, & rapamycin | The Peter Attia Drive Podcast (Ep 207, AMA 35)
At a glance
WHAT IT’S REALLY ABOUT
Why Aging Biomarkers and Epigenetic Clocks Remain Unproven, Say Attia and Kaeberlein
- The episode is a three-person AMA format built from audience questions about NAD precursors, rapamycin and metformin, with Matt Kaeberlein joining Peter Attia to compare the evidence for each.
- Both speakers agree that aging lacks a clear, validated biomarker comparable to ApoB in lipidology, though Kaeberlein feels the field is closer than it was fifteen or twenty years ago.
- Kaeberlein explains that epigenetic clocks use predictable age-related chemical marks on DNA and histones, but says no one has run the definitive experiment, such as a mouse lifespan study, showing the clocks predict outcomes.
- Attia says he relies on functional and phenotypic measures like VO2 max, strength, muscle mass and standard blood markers rather than epigenetic clocks, and Kaeberlein favors functional biomarkers too.
- Both express concern about commercial aging clocks, with Kaeberlein calling the sale of biological-age tests and products claiming to reverse that age dishonest and snake oil that the FDA should address.
IDEAS WORTH REMEMBERING
5 ideasAging lacks a validated biomarker like ApoB
Attia contrasts aging with lipidology, where ApoB is a clear causal marker to track; Kaeberlein agrees current aging biomarkers are still a work in progress.
Biological age markers may differ from rate-of-aging markers
Kaeberlein notes that a short-term readout of an intervention must reflect rate of aging or even reversal, which may not be the same signature as a measure of biological age.
Epigenetic clocks lack a definitive validation experiment
Kaeberlein says no one has shown in the same individuals or population that these clocks predict future outcomes after interventions, and he finds it bothersome that the mouse experiment hasn't been done.
Broader clocks may be more promising than methylation-only ones
Kaeberlein argues that clocks incorporating more than epigenetics are likelier to work, since epigenetics is only one of the nine hallmarks of aging; Attia doubts any signature will beat tried-and-true phenotypic tests.
Functional measures guide clinical confidence
Attia says confidence in a patient comes from improvements in VO2 max, muscle mass, strength, glucose disposal, ApoB and inflammatory markers, while Kaeberlein likes functional biomarkers because improvement across multiple organs suggests modulation of underlying aging biology.
WORDS WORTH SAVING
5 quotesit's still dishonest to claim to people that anyone is able to, with any precision, measure your biological age, and there are lots and lots of companies doing that.
— Dr. Matt Kaeberlein
It becomes a bigger problem when the same companies are then also selling a product that they claim will reverse your biological age. That's just snake oil.
— Dr. Matt Kaeberlein
The other is this is actually a pretty easy experiment to do in mice, and it really bothers me that nobody has done it.
— Dr. Matt Kaeberlein
I just have a hard time believing that there's going to be, um, a, an epigenetic signature that I think will be more valuable than some of the most tried and true phenotypic tests.
— Peter Attia
If you can make multiple organs and tissues function better with the same intervention, I think you can make a case that you are in fact modulating some underlying biology of aging as opposed to, to only the biology of that tissue and organ.
— Dr. Matt Kaeberlein
High quality AI-generated summary created from speaker-labeled transcript.
